Compare Stocks: DAWN, APGE, ALKS, and IBRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$48.33 +0.6%	$50.50	$25.17 ▼ $55.67	$8.06B	0.34	1.66 million shs	939,635 shs
APGE Apogee Therapeutics	$134.75	$129.31	$35.39 ▼ $134.88	$8.38B	0.34	1.26 million shs	948,283 shs
DAWN Day One Biopharmaceuticals	$21.53	$19.41	$5.64 ▼ $21.53	$2.22B	-1.74	1.52 million shs	2.99 million shs
IBRX ImmunityBio	$7.79 -0.6%	$7.78	$1.95 ▼ $12.43	$8.31B	0.03	8.87 million shs	7.59 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	+0.65%	-1.49%	-8.08%	+31.33%	+66.83%
APGE Apogee Therapeutics	0.00%	+0.15%	+0.50%	+66.03%	+274.10%
DAWN Day One Biopharmaceuticals	0.00%	0.00%	0.00%	0.00%	+216.15%
IBRX ImmunityBio	-0.64%	+2.91%	+3.73%	+7.89%	+244.69%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALKS Alkermes	$48.33 +0.6%	$50.50	$25.17 ▼ $55.67	$8.06B	0.34	1.66 million shs	939,635 shs
APGE Apogee Therapeutics	$134.75	$129.31	$35.39 ▼ $134.88	$8.38B	0.34	1.26 million shs	948,283 shs
DAWN Day One Biopharmaceuticals	$21.53	$19.41	$5.64 ▼ $21.53	$2.22B	-1.74	1.52 million shs	2.99 million shs
IBRX ImmunityBio	$7.79 -0.6%	$7.78	$1.95 ▼ $12.43	$8.31B	0.03	8.87 million shs	7.59 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALKS Alkermes	+0.65%	-1.49%	-8.08%	+31.33%	+66.83%
APGE Apogee Therapeutics	0.00%	+0.15%	+0.50%	+66.03%	+274.10%
DAWN Day One Biopharmaceuticals	0.00%	0.00%	0.00%	0.00%	+216.15%
IBRX ImmunityBio	-0.64%	+2.91%	+3.73%	+7.89%	+244.69%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALKS Alkermes	2.72	Moderate Buy	$54.56	12.90% Upside
APGE Apogee Therapeutics	2.20	Hold	$124.43	-7.66% Downside
DAWN Day One Biopharmaceuticals	2.00	Hold	$23.29	8.15% Upside
IBRX ImmunityBio	2.71	Moderate Buy	$14.20	82.28% Upside

Current Analyst Ratings Breakdown

Latest DAWN, APGE, ALKS, and IBRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/13/2026	APGE Apogee Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$81.00 ➝ $135.00
8/12/2026	APGE Apogee Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
8/7/2026	ALKS Alkermes	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
7/30/2026	ALKS Alkermes	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
7/29/2026	ALKS Alkermes	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$60.00 ➝ $61.00
7/29/2026	ALKS Alkermes	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$48.00 ➝ $58.00
7/28/2026	ALKS Alkermes	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$43.00 ➝ $65.00
7/20/2026	ALKS Alkermes	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$45.00 ➝ $63.00
7/17/2026	APGE Apogee Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/13/2026	ALKS Alkermes	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$61.00 ➝ $62.00
7/13/2026	ALKS Alkermes	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Neutral	$60.00

(Data available from 8/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALKS Alkermes	$1.67B	4.86	$1.69 per share	28.68	$10.78 per share	4.48
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$19.21 per share	N/A
DAWN Day One Biopharmaceuticals	$158.18M	14.06	N/A	N/A	$4.30 per share	5.01
IBRX ImmunityBio	$113.29M	72.88	N/A	N/A	($0.99) per share	-7.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALKS Alkermes	$241.66M	$0.38	127.19	201.38	N/A	3.96%	4.15%	2.19%	10/28/2026 (Estimated)
APGE Apogee Therapeutics	-$255.84M	-$4.34	N/A	N/A	N/A	N/A	-29.88%	-28.08%	11/9/2026 (Estimated)
DAWN Day One Biopharmaceuticals	-$107.32M	-$1.03	N/A	2,153.00	N/A	-67.85%	-23.43%	-20.69%	N/A
IBRX ImmunityBio	-$351.40M	-$0.97	N/A	N/A	N/A	-598.55%	N/A	-51.65%	11/3/2026 (Estimated)

Latest DAWN, APGE, ALKS, and IBRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/10/2026	Q2 2026	APGE Apogee Therapeutics	-$1.07	-$1.14	-$0.07	-$1.14	$10.00 million	N/A
8/4/2026	Q2 2026	IBRX ImmunityBio	-$0.08	-$0.22	-$0.14	-$0.22	$49.70 million	$51.24 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
DAWN Day One Biopharmaceuticals	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALKS Alkermes	0.82	2.30	1.85
APGE Apogee Therapeutics	N/A	26.44	26.44
DAWN Day One Biopharmaceuticals	N/A	8.02	7.91
IBRX ImmunityBio	N/A	5.72	5.70

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALKS Alkermes	95.21%
APGE Apogee Therapeutics	79.04%
DAWN Day One Biopharmaceuticals	87.95%
IBRX ImmunityBio	8.58%

Insider Ownership

Company	Insider Ownership
ALKS Alkermes	4.59%
APGE Apogee Therapeutics	24.30%
DAWN Day One Biopharmaceuticals	6.20%
IBRX ImmunityBio	66.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALKS Alkermes	2,050	167.76 million	160.06 million	Optionable
APGE Apogee Therapeutics	91	62.20 million	47.09 million	Optionable
DAWN Day One Biopharmaceuticals	60	103.33 million	96.93 million	Optionable
IBRX ImmunityBio	590	1.06 billion	359.28 million	Optionable

DAWN, APGE, ALKS, and IBRX Headlines

Recent News About These Companies

SLS, IBRX stocks in focus: Analyst says Moderna-Merck cancer vaccine success bodes well for oncology

August 21 at 8:23 AM | msn.com

Bell & Brown Wealth Advisors LLC Makes New $657,000 Investment in ImmunityBio, Inc. $IBRX

August 20 at 6:00 AM | defenseworld.netD

ImmunityBio, Inc. (NASDAQ:IBRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

August 19 at 4:28 AM | marketbeat.com

147,000 Shares in ImmunityBio, Inc. $IBRX Purchased by Hussman Strategic Advisors Inc.

August 15, 2026 | marketbeat.com

SLS and IBRX eye green weekly close: Vanguard’s major stakes in cancer drugmakers steal the spotlight

August 13, 2026 | msn.com

ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman

August 10, 2026 | aol.comA

Royal Bank of Canada Has $11.40 Million Holdings in ImmunityBio, Inc. $IBRX

August 9, 2026 | marketbeat.com

The Bull Case For ImmunityBio (IBRX) Could Change Following ANKTIVA’s Broad UAE Approval And Ongoing Losses

August 7, 2026 | finance.yahoo.com

Q3 Earnings Estimate for ImmunityBio Issued By HC Wainwright

August 6, 2026 | marketbeat.com

IBRX founder Soon-Shiong bets on Anktiva's next growth phase — ImmunityBio posts record Q2 sales

August 5, 2026 | msn.com

ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million

August 5, 2026 | aol.comA

IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake

August 5, 2026 | zacks.com

HC Wainwright Increases Earnings Estimates for ImmunityBio

August 5, 2026 | marketbeat.com

ImmunityBio (NASDAQ:IBRX) Posts Earnings Results, Misses Estimates By $0.14 EPS

August 4, 2026 | marketbeat.com

ImmunityBio (NASDAQ:IBRX) Shares Gap Down on Disappointing Earnings

August 4, 2026 | marketbeat.com

ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimates

August 4, 2026 | zacks.com

ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million

August 4, 2026 | businesswire.com

Cetera Investment Advisers Has $7.26 Million Stock Holdings in ImmunityBio, Inc. $IBRX

August 2, 2026 | marketbeat.com

Arete Wealth Advisors LLC Makes New Investment in ImmunityBio, Inc. $IBRX

August 1, 2026 | marketbeat.com

ImmunityBio Says Anktiva Receives UAE Marketing Authorization for Certain Bladder, Lung Cancers

July 30, 2026 | finance.yahoo.com

ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead Drug

July 30, 2026 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DAWN, APGE, ALKS, and IBRX Company Descriptions

Alkermes NASDAQ:ALKS

$48.33 +0.31 (+0.65%)

As of 08/21/2026 04:00 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Apogee Therapeutics NASDAQ:APGE

$134.75 0.00 (0.00%)

As of 08/21/2026 04:00 PM Eastern

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Day One Biopharmaceuticals NASDAQ:DAWN

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

ImmunityBio NASDAQ:IBRX

$7.79 -0.05 (-0.64%)

As of 08/21/2026 04:00 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DAWN, APGE, ALKS, and IBRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DAWN, APGE, ALKS, and IBRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DAWN, APGE, ALKS, and IBRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DAWN, APGE, ALKS, and IBRX Company Descriptions

Alkermes NASDAQ:ALKS

Apogee Therapeutics NASDAQ:APGE

Day One Biopharmaceuticals NASDAQ:DAWN

ImmunityBio NASDAQ:IBRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DAWN, APGE, ALKS, and IBRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DAWN, APGE, ALKS, and IBRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DAWN, APGE, ALKS, and IBRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DAWN, APGE, ALKS, and IBRX Company Descriptions

Alkermes NASDAQ:ALKS

Apogee Therapeutics NASDAQ:APGE

Day One Biopharmaceuticals NASDAQ:DAWN

ImmunityBio NASDAQ:IBRX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools